Mineralys Therapeutics (MLYS) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sarepta Therapeutics (SRPT) has outperformed Mineralys Therapeutics (MLYS) over the past year, losing 24.3% versus a loss of 41.3%. Mineralys Therapeutics is the larger company by market cap ($1.95 billion vs $1.85 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | SRPT |
|---|---|---|
| Share price | $22.09 | $17.50 |
| Market cap | $1.95B | $1.85B |
| 1-day change | +0.64% | +1.10% |
| YTD return | -39.13% | -18.68% |
| 1-year return | -41.34% | -24.31% |
| 5-year return | — | -79.21% |
| Forward P/E | — | 7.26 |
| EPS (TTM) | $-4.25 | $-1.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $47.65 | $24.68 |
| 52-week low | $21.50 | $14.68 |
| Distance from 52-week high | -53.64% | -29.09% |
| Analyst consensus | none | hold |
| Avg. price target upside | +119.56% | +24.17% |
| Average volume | 1.03M | 2.99M |
| Shares outstanding | 88.41M | 105.63M |
| Employees | 76 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRPT has outperformed MLYS by 17.0 percentage points over the past year.
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
MLYS vs SRPT FAQ
Which is bigger, Mineralys Therapeutics or Sarepta Therapeutics?
Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $1.95B compared with $1.85B for Sarepta Therapeutics (SRPT).
Which stock has performed better over the past year, MLYS or SRPT?
SRPT returned -24.31% over the past 12 months, compared with -41.34% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Mineralys Therapeutics and Sarepta Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.